調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

ナノメディシンの世界市場2015-2025

◆タイトル：Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025
◆商品コード：VGAIN5100107
◆調査・発行会社：visiongain
◆発行日：2015年9月
◆ページ数：131
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：製薬
◆販売価格オプション（消費税別）
Single UserGBP1,799 ⇒換算￥251,860見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算￥419,860見積依頼/購入/質問フォーム
Site License（全社内共有可）GBP4,999 ⇒換算￥699,860見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

 【レポートの概要】

当調査レポートでは、ナノメディシンの世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・ナノメディシンの世界市場
　（市場規模予測、市場の成長要因・阻害要因など）
・ナノメディシンの世界市場：主要製品別分析
・ナノメディシンの地域別市場分析、市場規模予測
・ナノメディシンの研究開発動向
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Nanopharma – Discover Revenue Prospects Now, Benefiting Your Authority
Do you want to find sales potentials of nanomedicine? If so, our new analysis gives you revenue forecasts to 2025 at overall world market, application, product and national level. That way you discover financial data, trends, R&D, opportunities and commercial outlooks.

Visiongain’s study gives you revenue predictions from 2015 for nano-enabled drugs. There you explore trends, technologies and expected products, benefiting your reputation for technological and commercial insight. Discover what the future holds, staying ahead.

Our work explains the potential of nanomedicine to change pharma. See how those developments affect patients, healthcare providers and pharmaceutical companies.

Please read on to explore what drives and shapes that industry, also seeing revenue prediction.

Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

Forecasts and other analysis show you where the best sales opportunities exist
Our new report shows revenue forecasting to 2025, recent results, growth rates and market shares. You explore quantitative and qualitative analyses, business news, research and development. You gain 34 tables, 44 charts and three interviews with other experts.

With that study you assess clinical, technological and commercial trends, results and potentials:
• Why will the nanopharma market expand fast – and what future revenues are possible?
• When will that worldwide industry achieve overall sales in hundreds of billion dollars?
• What products give the most promise for developers, producers and sellers?
• Who are the best-placed companies in that healthcare industry from 2015?
• Where are the most lucrative regions for selling those medicines?
• How will nanotechnological advances affect drug developers, marketers and manufacturers?

Many opportunities exist in healthcare for applications of nanotechnology. With our study you discover what segments are most likely to prosper. See potential sales from 2015.

Why struggle to find data, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations. With our research and analysis, see how to save time and benefit your authority on nanomedicine.

That way you explore what the future holds for nanopharma. The following sections outline how our new investigation helps your work.

Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

Predictions for that world market and submarkets – what sales growth is possible?
Along with revenue prediction for the overall world market for nanopharmaceuticals, our investigation shows you forecasts to 2025 for six individual therapeutic submarkets:
• Cancer
• Cardiovascular disorders
• Central nervous system (CNS) conditions
• Infectious diseases
• Inflammation
• Other applications of nanotechnology in pharmacotherapy.

Our report analyses sales potentials of those technological advances, showing how companies gain. That work can also benefit your authority on nanomedical applications, expanding your reputation for commercial and technological knowledge.

The new investigation discusses what stimulates and restrains sales of those treatments. You explore that industry, also seeing what products can achieve the most success.

Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

Forecasting of leading products’ sales – what revenues are possible for nanodrugs?
How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of 13 brands:
• Abraxane
• Alimta
• Eligard
• Copaxone
• Rapamune
• Neulasta
• Cimzia.

Our sales predictions also cover these products:
• AmBisome
• MIRCERA
• Pegasys
• Emend
• Renagel
• Ritalin.

That work shows how high sales can go, revealing drugs and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, R&D, competitors and opportunities.

Discover what the future holds. Our study also divides its overall world forecast into geographical segments.

Regional markets for nanomedicine – where will highest sales and growth occur?
Developments worldwide will influence the nano-enabled drugs market, raising demand for those therapies in developed and developing countries. Discover what success is possible.

Our analyses show you individual revenue forecasts to 2025 for five regional markets:
• United States
• Japan
• European Union
• Asia Pacific
• Rest of world.

There you discover progress and outlooks. You assess the nanomedical industry’s future – needs, developments, demands and their meaning. Our work explains, exploring issues affecting nanotechnological companies, influencing their work, results and potentials.

Forces affecting the nanopharma business – what shapes its present and future?
Our new report discusses pressures, opportunities and other events affecting the nanopharmaceutical industry and market from 2015, including these influences:
• Prominent nanomedicine companies by region – leading players
• Systems used in nanotechnology-enabled drug delivery
• Applications in therapeutics, implants, diagnostics and theranostics
• Nanoparticles – liposomes, polymers, quantum dots, superparamagnetic iron oxide (SPIO), carbon nanotubes and nanoshells
• Nanoparticle function, targeting, surface conjugation, improved bioavailability, tunability and controlled release systems
• Investments, infrastructure, networks and collaborations, as well as outlooks for regulatory guidelines and harmonisation.

Our survey also discusses research and development in nanomedicine, in particular for these product candidates:
• DermaVir (Genetic Immunity)
• CRLX101 (Cerulean Pharma)
• CPX-351 (Celator Pharma)
• NC-6004 (NanoCarrier)
• NK-105 (Nippon Kayaku)
• NK-012 (Nippon Kayaku)
• SGT-53 (SynerGene Therapeutics)
• BIND-014 (BIND Biosciences)
• ThermoDox (Celsion)
• ADI-PEG 20 (Polaris).

You assess the nanomedicine industry’s strengths, weaknesses, opportunities and threats. That way you explore what restricts and stimulates companies, seeing what is possible.

Avoid falling behind. With our investigation you discover what the future holds for nano-enabled drugs, seeing prospects for their designers, producers and sellers.

Leading companies and overall 2017 revenue prediction
From 2015, product launches using nanotechnology hold great potential for investments, demand and sales. Our study predicts the world market for nanopharmaceuticals will reach $130bn in 2017, with strong revenue expansion from 2015 to 2025. Explore the potentials.

Our work assesses nanopharma technologies, products and companies holding the best prospects. You see what is possible for technological advances and revenue expansion.

Those analyses cover these companies and other developers, producers, marketers and technology suppliers:
• Sanofi
• BIND Therapeutics
• Merck
• Pfizer
• Cerulean Pharma
• Selecta Biosciences.

And you assess these nanopharma specialists, among others:
• Nanobiotix
• Magforce
• Celgene
• Celsion Corporation
• Nanocarrier.

You also examine three interviews with authorities in these organisations:
• Swiss Federal Laboratories for Materials Science and Technology
• Rexahn Pharmaceuticals
• Cristal Therapeutics.

From 2015 there will arise many opportunities. Our work shows you commercial possibilities for those novel drug technologies, helping you stay ahead in knowledge and succeed.

Ways Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025 helps
In the following main ways, our investigation helps your research, analyses, decisions, proposals and presentations:
• Revenues for nanopharma to 2025 at overall world level and for 6 submarkets and 13 products – find outlooks for R&D, production and sales
• Forecasts to 2025 for 5 regional markets – assess leading countries and regions for potential revenues, seeing what progress is possible
• Prospects for established competitors and rising companies – explore portfolios, results, strategies, technologies and outlooks for success
• Analysis of what encourages and restrains the nanomedicine industry – investigate challenges, strengths and competition affecting revenues and profits
• Interviews with authorities – discover what other experts think, say and do, helping you stay ahead in technological, medical and commercial insight.

That study – by visiongain’s in-house analysts in the UK – gives knowledge to help your work, to spare you hassle and save time. You gain data leading companies depend on.

【レポートの目次】

1. Report Overview
1.1 Overview of the Nanomedicine Industry and Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Nanomedicine
2.1 Nanotechnology – Definition
2.2 Nanomedicine – Size Should Not be the Main Definition
2.3 Nanotechnology – Solutions and Improvements in Medicine
2.4 Nanomedicine – Types of Applications
2.4.1 Drug Delivery
2.4.2 Nanodrugs
2.4.2.1 Nanoparticles – Combinations of Three Dimensions
2.4.2.1.1 Liposomes
2.4.2.1.2 Polymers
2.4.2.1.3 Quantum Dots
2.4.2.1.4 Superparamagnetic Iron Oxide (SPIO)
2.4.2.1.5 Carbon Nanotubes
2.4.2.1.6 Carbon Nanoshells
2.4.2.2 Nanoparticle Functionalisation
2.4.2.2.1 Targeting
2.4.2.2.2 Surface Conjugation
2.4.2.2.3 Improved Bioavailability
2.4.2.2.4 Tunability
2.4.2.2.5 Controlled Release
2.4.3 Implants
2.4.4 Diagnostics
2.4.4.1 Diagnostic Tools
2.4.4.2 Medical Instruments
2.4.4.3 Imaging Tools
2.4.4.4 Theranostics

3. Global Nanomedicine Market, 2015-2025
3.1 Revenue Forecasts of Nanomedicine by Therapeutic Area
3.1.1 Forecast of Nanomedicine for Oncology 2015-2025
3.1.2 Forecast of Nanomedicine for Cardiovascular Uses 2015-2025
3.1.3 Forecast of Nanomedicine for Anti-inflammatory Uses 2015-2025
3.1.4 Forecast of Nanomedicine for Neurology 2015-2025
3.1.5 Forecast of Nanomedicine for Anti-Infective 2015-2025
3.1.6 Forecast of Nanomedicine for Other Therapeutic Areas 2015-2025

4. Nanomedicine Products – Commercial Outlooks from 2015
4.1 Nanomedicine Products – Segmentation
4.1.1 Nanomedicine Products in the Market – Revenue Potentials, 2015-2025
4.1.1.1 Abraxane (Celgene)
4.1.1.2 Doxil (Janssen)
4.1.1.3 Myocet (Teva Pharmaceuticals)
4.1.1.4 ONCASPAR (Baxalta)
4.1.1.5 Alimta (Eli Lilly)
4.1.1.6 Eligard (Sanofi)
4.1.1.7 DaunoXome (Galen)
4.1.1.8 Copaxone (Teva)
4.1.1.9 Rapamune (PF Prism)
4.1.1.10 Neulasta (Amgen)
4.1.1.11 Cimzia (UCB)
4.1.1.12 AmBisome (Astellas Pharma)
4.1.1.13 MIRCERA (Roche)
4.1.1.14 Pegasys (Roche)
4.1.1.15 Emend (Merck)
4.1.1.16 Renagel (Genzyme)
4.1.1.17 Ritalin (Novartis)

5. Leading National Markets, 2015-2025
5.1 Nanomedicine – Leading Markets, 2014
5.2 The US Nanomedicine Market, 2015-2025
5.3 The Japanese Nanomedicine Market, 2015-2025
5.4 The EU Nanomedicine Market, 2015-2025
5.5 The Asia-Pacific Nanomedicine Market, 2015-2025
5.6 Rest of the World Nanomedicine Market, 2015-2025

6. Profiles of Pharmaceutical Companies with Nanotechnology Related Applications
6.1 Sanofi
6.2 BIND Therapeutics
6.3 Merck
6.4 Pfizer
6.5 Cerulean Pharma
6.6 Selecta Biosciences
6.7 Nanobiotix
6.8 Magforce
6.9 Celgene
6.10 Celsion Corporation
6.11 Nanocarrier

7. Research & Development
7.1 Nanoparticles and Nano-enabled Drugs in the Pipeline
7.1.1 DermaVir (Genetic Immunity)
7.1.2 CRLX101 (Cerulean Pharma)
7.1.3 CPX-351 (Celator Pharma)
7.1.4 NC-6004 (NanoCarrier Co.)
7.1.5 NK-105 (Nippon Kayaku Co. Ltd.)
7.1.6 NK-012 (Nippon Kayaku Co. Ltd.)
7.1.7 SGT-53 (SynerGene Therapeutics)
7.1.8 BIND-014 (BIND Biosciences)
7.1.9 ThermoDox (Celsion)
7.1.10 ADI-PEG 20 (Polaris)

8. Qualitative Analysis of the Nanomedicine Market, 2015
8.1 Room for Improvement
8.1.1 Safety and Toxicology Often Yet to be Determined
8.1.2 Establishment of Structures and Collaborations
8.1.3 Regulatory – The Need for Clear Guidelines and Harmonization

9. Research Interviews, 2015
9.1 Dr Peter Wick, Empa, the Swiss Federal Laboratories for Materials Science and Technology
9.1.1 Connecting the Key Players in the Nanomedical Sector in Europe
9.1.2 Nanomedicine Industry in Europe – In Need of an Infrastructure
9.1.3 EU-NCL: Bridging the Major Gaps and Challenges
9.2 Dr Peter D. Suzdak, CEO, Rexahn Pharmaceuticals
9.2.1 Precision-Targeted Therapy – Revolutionizes Cancer Treatment
9.2.2 RX-21101 – Included in NCL’s Preclinical Characterization Program
9.2.3 Rexahn’s NPDCS Technology – Next Generation Approach to Chemotherapy
9.2.4 Rexahn’s Polymer-Drug Conjugate – Improves Efficacy and Reduces Side Effects
9.3 Dr Joost Holthuis, CEO, Cristal Therapeutics, Netherlands
9.3.1 Nanomedicine Industry in Europe
9.3.2 CriPec Based Nanomedicines – Overcome the Drawbacks of Conventional Therapies
9.3.3 CriPec Platform – All the Best Features in a Single System
9.3.4 CriPec Docetaxel – Lead Candidate Product
9.3.5 In Development – CriPec Actively Targeted Nanoparticles Platform
9.3.6 Competitive Advantage Can be Achieved Through Partnering of Parties

10. Conclusions of the Research and Analysis
10.1 Nanotechnology Holds Great Promise in Healthcare
10.2 More Research Needed to Establish Safety
10.3 Harmonization in Definition and Guidelines

Table 1.1 The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 2.1 Advantages of Nanotechnology in Medicine
Table 2.2 Challenges and Solutions - NDDS
Table 3.1 The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.2 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.1 Abraxane Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.2 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.3 Eligard Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.4 Copaxone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.5 Rapamune Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.6 Neulasta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.7 Cimzia Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.8 AmBisome Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.9 MIRCERA Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.10 Pegasys Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.11 Emend Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.12 Renagel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.13 Ritalin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.1 Nanomedicine Market Revenues ($bn) for Leading Regions, 2014-2025
Table 5.2 Nanomedicine Market Share(%) by Leading Regions, 2014-2025
Table 5.3 Prominent Nanomedicine Companies in the US, 2014
Table 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.7 Prominent Nanomedicine Companies in the UK, 2014
Table 5.8 Prominent Nanomedicine Companies in Germany, 2014
Table 5.9 Prominent Nanomedicine Companies in France, 2014
Table 5.10 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.11 RoW Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 8.1 Strengths, Weaknesses, Opportunities and Threats in the Nanomedicine Market, 2015

Figure 1.1 Nanomedicine - Segmented by Application
Figure 2.1 Applications of Nanotechnology in Diagnostics
Figure 2.2 Applications of Nanotechnology in Therapeutics
Figure 2.3 Systems Used in Nanotechnology-enabled Drug Delivery
Figure 2.4 Market Shares of NDDS by System, 2014
Figure 2.5 NDDS: Market Drivers and Restraints, 2015-2025
Figure 2.6 Representation of Nanoparticles
Figure 2.7 Combinations of Layers that Form Nanoparticles
Figure 2.8 Nanoparticles: Market Drivers and Restraints 2015-2025
Figure 2.9 Implants: Market Drivers and Restraints, 2015-2025
Figure 2.10 Diagnostics: Market Drivers and Restraints, 2015-2025
Figure 2.11 Theranostics: Market Drivers and Restraints, 2015-2025
Figure 3.1 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), 2015-2025
Figure 3.2 Applications of Nanotechnology in the Cardiovascular Therapeutic Area
Figure 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), 2015-2025
Figure 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), 2015-2025
Figure 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), 2015-2025
Figure 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), 2015-2025
Figure 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), 2015-2025
Figure 4.1 Nanomedicine - Segmented by Application
Figure 4.2 Proportions of Nano Products by Application, 2014
Figure 4.3 Proportions of Nano Products by Therapeutic Area, 2014
Figure 4.4 Abraxane Revenue Forecast ($bn), 2015-2025
Figure 4.5 Alimta Revenue Forecast ($bn), 2015-2025
Figure 4.6 Eligard Revenue Forecast ($bn), 2015-2025
Figure 4.7 Copaxone Revenue Forecast ($bn), 2015-2025
Figure 4.8 Rapamune Revenue Forecast ($bn), 2015-2025
Figure 4.9 Neulasta Revenue Forecast ($bn), 2015-2025
Figure 4.10 Cimzia Revenue Forecast ($bn), 2015-2025
Figure 4.11 AmBisome Revenue Forecast ($bn), 2015-2025
Figure 4.12 MIRCERA Revenue Forecast ($bn), 2015-2025
Figure 4.13 Pegasys Revenue Forecast ($bn), 2015-2025
Figure 4.14 Emend Revenue Forecast ($bn), 2015-2025
Figure 4.15 Renagel Revenue Forecast ($bn), 2015-2025
Figure 4.16 Ritalin Revenue Forecast ($bn), 2015-2025
Figure 5.1 Leading National Nanomedicine Markets by Share of Global Market (%), 2014
Figure 5.2 Leading National Nanomedicine Markets by Share of Global Market (%), 2019
Figure 5.3 Leading National Nanomedicine Markets by Share of Global Market (%), 2025
Figure 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.7 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.8 RoW Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 7.1 Proportion of Products by Therapeutic Area in Clinical Trials, 2014
Figure 7.2 Products in Clinical Trials by Developmental Phase, 2014

【レポートのキーワード】

ナノメディシン、治療、用途、ナノ技術、医薬品、アブラキサン、ドキシル、製薬

★調査レポート[ナノメディシンの世界市場2015-2025] ( Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025 / VGAIN5100107) 販売に関する免責事項
[ナノメディシンの世界市場2015-2025] ( Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025 / VGAIN5100107) についてEメールでお問い合わせ
◆関連調査資料◆
  • 臨床試験アウトソーシングサービスの世界市場2015-2025
    VGAIN50614 / visiongain / 2015年6月 / 当調査レポートでは、臨床試験アウトソーシングサービスの世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・臨床試験アウトソーシングサービスの世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・主要先進国の臨床試験アウトソーシングサービス市場分析、市場規模予測 ・主要新興国の臨床試験アウトソーシングサービス市場分析、市場規模予測 ・市場動向 ・主要CRO（医薬品開発受託機関）分析 ・専門家の見解...Clinical Trials – Discover Commercial Potentials of Outsourced Drug Testing, Benefiting Your Authority What does the future hold for pharmaceutical clinical research providers? Visiongain’s new study gives you multilevel revenue forecasts from 2015 to 2025. It explains trends, opportunities and selling prospects for that drug development and testing. Our report predicts sales at overall world market, submarket and national level. There you find the most promising and lucrative parts of clinical trial outsourcing, helping your research and analysis. That way stay ahead, saving time and hassle, also benefiting your influence. Clinical research organisations (CROs) and drug companies using them will...
  • 自動車タイヤの世界市場2015-2025
    VGAIN50601 / visiongain / 2015年5月 / 当調査レポートでは、自動車タイヤの世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・自動車タイヤの世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・地域別市場分析、市場規模予測 　（ヨーロッパ、北米、アジア、南米、アフリカ、中東市場） ・自動車タイヤの世界市場：タイヤサイズ別市場分析 ・市場環境分析 ・主要企業分析...Visiongain’s new report calculates that the world market for automotive tires will reach $198.78bn in 2015 and the market is a dynamic and fast changing business. The automotive tires market can broadly be divided into two divisions -original equipment tires fitted by the vehicle manufacturer at the factory and the replacement aftermarket. Tires fitted as original equipment naturally follow the global automotive business and the cyclical nature of this business. As new segments of vehicle become more popular new variations of tires are needed and this is one of the drivers of innovation. As vehicles such as sport utility vehicles...
  • ラテンアメリカの製薬市場2015-2025
    VGAIN5100112 / visiongain / 2015年9月 / ...What can be expected from the Latin American pharmaceutical market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there. Our 140-page report provides 121 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market. Forecasts from 2015-2025 and other analyses...
  • 世界における主要な幹細胞技術企業分析2015-2025
    VGAIN5040804 / visiongain / 2015年3月 / ...Stem cell specialists for healthcare – discover what the future holds for those companies Who are the top stem cell developers and producers? And what are their sales outlooks? Visiongain’s new report shows you their potentials from 2015. There you discover therapies, results, trends in research and development, opportunities and revenue forecasts. That way you find data and analysis on cellular technologies transforming human medicine. Our study analyses 23 leading companies in the US, Europe, Israel and Asia-Pacific. There you hear how stem cell producers can progress and gain, discovering their potentials. Please read on, then, to scan those organisations...
  • 冷凍加工食品の世界市場予測2015-2025
    VGAIN5050806 / visiongain / 2015年4月 / 当調査レポートでは、冷凍加工食品の世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・冷凍加工食品の世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・冷凍加工食品の世界市場：種類別市場分析 ・地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...Chilled processed food is a relatively new sector of the global food market. Its current stage of development varies from country to country depending on many factors from social to economic. The industry is well developed in some countries. However, market players still have to overcome many obstacles in order to succeed in the chilled food sector in other regions of the market. North America and Europe currently represent the major markets in the chilled processed food industry. At the same time, we also expect growth in developing regions albeit at a smaller scale since the market still has to...
  • オイルサンドの世界市場2015-2025
    VGAIN50608 / visiongain / 2015年5月 / 当調査レポートでは、オイルサンドの世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・オイルサンドの世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・オイルサンドの世界市場：セグメント別市場分析 ・地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...The oil sands market will experience a dramatic downturn in 2015 as the impact of the oil price fall impacts upon project economics and company budgets. An almost equally significant decline will be seen in 2018 as the last under-construction oil sands mining and upgrading projects are completed. The extent to which oil sands investment recovers over subsequent years will be highly dependent upon oil prices. Oil sands are towards the top end of the cost spectrum in terms of oil resource development, though there is a significant difference between the break even prices of new in-situ and oil sands...
  • 硬質プラスチック包装の世界市場2015-2025
    VGAIN50610 / visiongain / 2015年5月 / 当調査レポートでは、硬質プラスチック包装の世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・硬質プラスチック包装の世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・硬質プラスチック包装の世界市場：需要先（産業）別市場分析 ・硬質プラスチック包装の世界市場：樹脂種類別市場分析 ・地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解...The surging economies in the developing nations, the expansion of the on-the-go lifestyle and the ageing population are significantly increasing demand for more convenient, easy-to-carry, light, safe and functional packaging, without comprising on the barrier properties and cost effectiveness. This has given rise to a boom in the rigid plastic packaging market as rigid plastic is a light, malleable and durable material that can adapt to various packaging designs and requirements. It is also a cost-effective choice of packaging. Visiongain estimates that the global rigid plastic packaging market will reach $167.4 billion in 2015. This brand new report from visiongain...
  • 世界のコネクテッドカー市場2015-2025
    VISION411211 / visiongain / 2014年11月 / 当調査レポートでは、世界のコネクテッドカー市場について調査・分析し、エグゼクティブサマリー、コネクテッドカー市場の概況、接続方式別の市場予測、サービスプロバイダー別の市場予測、出荷台数の予測、世界の各地域別市場予測、市場環境分析、専門家の見解、主要企業などのデータをお届けいたします。...The increased demand for wireless connectivity, demonstrated by the high level of penetration of smartphones and tablets, drives the automotive industry to adjust to a new lifestyle consensus and incorporate in-vehicle internet connectivity solutions. Moreover, global regulatory mandates (eCall in EU, GLONASS in Russia, Contran 245 in Brazil) require the usage of telematics for safety purposes and the installation of basic Telematics Control Units (TCU) in all new vehicles in Europe from 2017 and in other countries from 2016 onwards. These factors offer the opportunity for new revenue streams and enhancement of customer loyalty for the Connected Car ecosystem. On...
  • グラフェンの世界市場予測2015-2025
    VGAIN5050803 / visiongain / 2015年4月 / 当調査レポートでは、グラフェンの世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・グラフェンの世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・グラフェンの世界市場：用途別市場分析 ・地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...The graphene market is very new and in the embryonic stage with only a few products being commercialised yet. However, we forecast an increasing number of graphene companies will drive investment over the coming years resulting in wider adoption of graphene across a range of industries. The graphene market has been dominated by North America, accounting for a large share in the global market, followed by Europe. However, we expect Asia-Pacific to be the fastest growing region for adoption of graphene. Europe and North America regions are also expected to have strong, above the global trend, growth. For 2015 we...
  • 民間ヘリコプターの世界市場予測2015-2025
    VGAIN5050802 / visiongain / 2015年4月 / 当調査レポートでは、民間ヘリコプターの世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・民間ヘリコプターの世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・民間ヘリコプターの世界市場：航空機重量別市場分析 ・地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...Civil helicopters extend the reach and expand the capabilities of businesses, governments and security agencies. The positive impact of civil helicopters for entities that can afford to acquire and operate them remains compelling. However, purchases must also be weighed against the prevailing economic conditions. For decades, the civil helicopter market was one of the smallest segments in the aerospace industry, with a market size of just $2bn each year. The situation changed in 2005, when the civil helicopter market entered its fastest growth phase. However, the civil helicopter industry, as with other industries, remains affected by economic uncertainty in parts...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆